

Special Issue

Current Development of Vaccines for Respiratory Viral Infection

Message from the Guest Editor

Viral respiratory tract infections constitute a substantial disease burden in the population, particularly among young children and older adults. More than 25 viruses have been linked to respiratory infections, including common respiratory pathogens such as rhinovirus (RV), respiratory syncytial virus (RSV), influenza virus (Flu), human metapneumovirus (hMPV), parainfluenza viruses (PIV) and human coronaviruses (CoVs). This Special Issue of *Vaccines* focuses on the most recent progress and current vaccine development trends in the field of respiratory viral infection. We invite you to contribute with an original research article, review or perspective on the latest research to highlight novel experimental vaccine candidates, scientific data on supporting vaccine strategies, immune responses elicited by a novel vaccine and concerns and optimisations relating vaccine strategies. This Special Issue emphasises major infectious diseases caused by respiratory viruses, but related topics on co-infections are also welcomed. We look forward to receiving your contributions.

Guest Editor

Dr. Ting Shi

College of Medicine and Veterinary Medicine, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK

Deadline for manuscript submissions

closed (30 April 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/178731

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).